发挥医保对医药创新引领作用的路径研究:建立医保创新药物发展基金的设想  

Study on the Path of Medical Insurance's Encouragement and Guidance on Pharmaceutical Industry Innovation: The Conception of “Medical Insurance Innovative Drug Development Fund”

作　　者：孙圆圆[1] 魏靖哲 蒋蓉[1] 邵蓉[1] SUN Yuan-yuan;WEI Jing-zhe;JIANG-rong

机构地区：[1]中国药科大学国家药物政策与医药产业经济研究中心,南京211198

出　　处：《中国卫生经济》2018年第12期33-36,共4页Chinese Health Economics

基　　金：2015年度国家社科基金重大项目(第二批)(15ZDB167)

摘　　要：我国创新药医保覆盖率低,未能充分发挥医保对医药创新的激励作用。发达国家常采用补充医疗保险的形式对创新药进行支付,有效地促进了医药再创新进程。通过参考国外典型补充保险制度,提出建立我国"创新药物发展基金"的设想,并从基金设立、运作、维持三方面构建"创新药物发展基金"基本架构,为发挥医保对医药产业创新的激励与引导作用设计新路径。Because of low coverage of innovative drugs, medical insurance payment could not play an incentive role on innovative drugs. Foreign developed countries often adopt the form of supplementary medical insurance to pay for innovative drugs, promoting the process of pharmaceutical re-innovation effectively. It delivered a conception of “Medical Insurance Innovative Drug Development Fund” referring to typical supplementary insurance system in foreign countries. It constructed the basic framework of “Medical Insurance Innovative Drug Development Fund” based on fund establishment, operation and maintenance, expecting to design a new approach to bring into full play the medical insurance’s encouragement and guidance on pharmaceutical industry innovation.

关 键 词：医疗保险 医保创新药物发展基金 医药创新 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] F840.613[经济管理—保险]